Aliases & Classifications for Hair Disease

MalaCards integrated aliases for Hair Disease:

Name: Hair Disease 12 15
Hair Diseases 45 74
Hair Disorder 56
Hair Problems 44

Classifications:



External Ids:

Disease Ontology 12 DOID:421
MeSH 45 D006201
NCIt 51 C34656
ICD10 34 L67.9
UMLS 74 C0018500

Summaries for Hair Disease

MedlinePlus : 44 The average person has 5 million hairs. Hair grows all over your body except on your lips, palms, and the soles of your feet. It takes about a month for healthy hair to grow half an inch. Most hairs grow for up to six years and then fall out. New hairs grow in their place. Hair helps keep you warm. It also protects your eyes, ears and nose from small particles in the air. Common problem with the hair and scalp include hair loss, infections, and flaking.

MalaCards based summary : Hair Disease, also known as hair diseases, is related to monilethrix and hypotrichosis 7, and has symptoms including pruritus and exanthema. An important gene associated with Hair Disease is KRT86 (Keratin 86), and among its related pathways/superpathways are Developmental Biology and Keratinization. The drugs Clobetasol and Minoxidil have been mentioned in the context of this disorder. Affiliated tissues include skin, brain and eye, and related phenotypes are no effect and Mildly decreased CFP-tsO45G cell surface transport

Disease Ontology : 12 An integumentary system disease that is located in hair.

Wikipedia : 77 Hair diseases are disorders primarily associated with the follicles of the... more...

Related Diseases for Hair Disease

Diseases in the Hair Disease family:

Hair-an Syndrome

Diseases related to Hair Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 38, show less)
# Related Disease Score Top Affiliating Genes
1 monilethrix 31.2 DSG4 KRT74 KRT81 KRT83 KRT86 LPAR6
2 hypotrichosis 7 31.0 DSG4 KRT25 KRT74 LIPH LPAR6
3 hypotrichosis 29.6 DCAF17 DSG4 HOXC13 KRT25 KRT71 KRT74
4 woolly hair syndrome 29.0 DSP KRT25 KRT71 KRT74 LIPH LPAR6
5 alopecia 28.8 ANTXR1 DCAF17 DSP FOXN1 KRT86 MBTPS2
6 menkes disease 11.7
7 ringed hair 11.2
8 hypertrichosis 10.7
9 trichomalacia 10.7
10 loose anagen hair syndrome 10.7
11 hypotrichosis simplex 10.2 DSG4 LIPH LPAR6
12 first-degree atrioventricular block 10.2 DSG4 KRT74
13 arrhythmogenic right ventricular dysplasia, familial, 9 10.1 DSP KRT74
14 arrhythmogenic right ventricular dysplasia, familial, 8 10.1 DSP KRT74
15 ectodermal dysplasia 4, hair/nail type 10.1 HOXC13 KRT74
16 alopecia universalis congenita 10.0 FOXN1 LIPH MBTPS2
17 hypotrichosis 6 10.0 DSG4 KRT74 LIPH LPAR6
18 cardiomyopathy, dilated, with woolly hair and keratoderma 10.0 DSP KRT74
19 ectodermal dysplasia 10.0 DSP HOXC13 KRT74
20 hypotrichosis 13 9.9 KRT25 KRT71 KRT74 LIPH
21 hypotrichosis 8 9.9 DSG4 KRT25 KRT74 LIPH LPAR6
22 mitochondrial complex iv deficiency 9.7
23 wilson disease 9.7
24 alopecia, androgenetic, 1 9.6
25 aging 9.6
26 pseudofolliculitis barbae 9.6
27 androgenic alopecia 9.6
28 connective tissue disease 9.6
29 rapidly involuting congenital hemangioma 9.6
30 bladder diverticulum 9.6
31 argininosuccinic aciduria 9.6
32 ataxia-telangiectasia 9.6
33 melanosis, neurocutaneous 9.6
34 ataxia and polyneuropathy, adult-onset 9.6
35 trichothiodystrophy 1, photosensitive 9.6
36 bartter disease 9.6
37 telangiectasis 9.6
38 cerebellar degeneration 9.6

Graphical network of the top 20 diseases related to Hair Disease:



Diseases related to Hair Disease

Symptoms & Phenotypes for Hair Disease

UMLS symptoms related to Hair Disease:


pruritus, exanthema

GenomeRNAi Phenotypes related to Hair Disease according to GeneCards Suite gene sharing:

27 (showing 2, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 ANTXR1 DCAF17 DSG4 DSP ERCC3 FOXN1
2 Mildly decreased CFP-tsO45G cell surface transport GR00360-A-1 9.65 ANTXR1 DCAF17 DSP ERCC3 FOXN1 KRT83

MGI Mouse Phenotypes related to Hair Disease:

47 (showing 1, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.32 DSG4 DSP ERCC3 FOXN1 HOXC13 KRT25

Drugs & Therapeutics for Hair Disease

Drugs for Hair Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 286, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clobetasol Approved, Experimental, Investigational Phase 4,Phase 3 25122-46-7, 25122-41-2 5311051 32798
2
Minoxidil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 38304-91-5 4201
3
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 124-94-7 31307
4
Prednisolone phosphate Approved, Vet_approved Phase 4,Not Applicable 302-25-0
5
Methylprednisolone hemisuccinate Approved Phase 4,Not Applicable 2921-57-5
6
Prednisolone Approved, Vet_approved Phase 4,Not Applicable 50-24-8 5755
7
Methylprednisolone Approved, Vet_approved Phase 4,Not Applicable 83-43-2 6741
8
Finasteride Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 98319-26-7 57363
9
Bimatoprost Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 155206-00-1 5311027
10
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
11
Ketoconazole Approved, Investigational Phase 4 65277-42-1 47576
12
Latanoprost Approved, Investigational Phase 4,Not Applicable 130209-82-4 5311221 5282380
13
Betamethasone Approved, Vet_approved Phase 4,Phase 2 378-44-9 9782
14 Orange Approved Phase 4,Not Applicable
15
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
16
Hydroxychloroquine Approved Phase 4 118-42-3 3652
17
Capsaicin Approved Phase 4,Not Applicable 404-86-4 1548943
18
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
19
Prilocaine Approved Phase 4 721-50-6 4906
20
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
21
Retapamulin Approved Phase 4 224452-66-8 6918462
22
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
23
Cephalexin Approved, Investigational, Vet_approved Phase 4 15686-71-2 27447
24
Tofacitinib Approved, Investigational Phase 4,Phase 2,Not Applicable 477600-75-2
25
Spironolactone Approved Phase 4,Phase 2 1952-01-7, 52-01-7 5833
26
Apremilast Approved, Investigational Phase 4,Not Applicable 608141-41-9 11561674
27
Ornithine Approved, Nutraceutical Phase 4,Phase 2 70-26-8, 3184-13-2 6262
28
Prednisolone hemisuccinate Experimental Phase 4,Not Applicable 2920-86-7
29 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Emollients Phase 4
32 glucocorticoids Phase 4,Phase 3,Phase 2,Not Applicable
33 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
34 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Antihypertensive Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
37 Vasodilator Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
38 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
40 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Not Applicable
41 Triamcinolone hexacetonide Phase 4,Phase 2,Not Applicable
42 Immunologic Factors Phase 4,Phase 3,Phase 2,Not Applicable
43 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
44 triamcinolone acetonide Phase 4,Phase 2,Not Applicable
45 Triamcinolone diacetate Phase 4,Phase 2,Not Applicable
46 Respiratory System Agents Phase 4,Phase 2,Phase 3,Phase 1
47 Anti-Asthmatic Agents Phase 4,Phase 2,Phase 3,Phase 1
48 Antiemetics Phase 4,Not Applicable
49 Autonomic Agents Phase 4,Phase 1,Phase 2,Not Applicable
50 Gastrointestinal Agents Phase 4,Not Applicable
51 Methylprednisolone Acetate Phase 4,Not Applicable
52 Protective Agents Phase 4,Phase 1,Phase 2,Not Applicable
53 Prednisolone acetate Phase 4,Not Applicable
54 Neuroprotective Agents Phase 4,Phase 2,Not Applicable
55 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
56 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1,Not Applicable
57 Adjuvants, Immunologic Phase 4,Phase 2,Not Applicable
58 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Not Applicable
59 Anesthetics Phase 4,Phase 1,Not Applicable
60 Central Nervous System Depressants Phase 4,Phase 2,Early Phase 1
61 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Not Applicable
62 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2,Not Applicable
63 Analgesics Phase 4,Phase 1,Phase 2,Early Phase 1,Not Applicable
64 5-alpha Reductase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
65 Ophthalmic Solutions Phase 4,Phase 2,Not Applicable
66 Cytochrome P-450 Enzyme Inhibitors Phase 4
67 Cytochrome P-450 CYP3A Inhibitors Phase 4
68 Antifungal Agents Phase 4
69 Antiprotozoal Agents Phase 4,Phase 2
70 Antiparasitic Agents Phase 4,Phase 2
71 Betamethasone sodium phosphate Phase 4,Phase 2
72 Betamethasone benzoate Phase 4,Phase 2
73 Betamethasone Valerate Phase 4,Phase 2 2152-44-5
74 Betamethasone-17,21-dipropionate Phase 4,Phase 2
75 interferons Phase 4,Not Applicable
76 Interferon Inducers Phase 4
77 Antimalarials Phase 4
78 Antipruritics Phase 4
79 Lidocaine, Prilocaine Drug Combination Phase 4
80 Diuretics, Potassium Sparing Phase 4,Phase 2
81 Anti-Arrhythmia Agents Phase 4
82 Anesthetics, Local Phase 4
83 Sodium Channel Blockers Phase 4
84 methicillin Phase 4,Not Applicable
85 Clindamycin phosphate Phase 4
86 Clindamycin palmitate Phase 4
87 Protein Kinase Inhibitors Phase 4,Phase 2,Not Applicable
88 Insulin, Globin Zinc Phase 4,Not Applicable
89 insulin Phase 4,Not Applicable
90 Mineralocorticoids Phase 4,Phase 2
91 Natriuretic Agents Phase 4,Phase 2
92 Mineralocorticoid Receptor Antagonists Phase 4,Phase 2
93 diuretics Phase 4,Phase 2
94 Janus Kinase Inhibitors Phase 4,Phase 2
95 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Not Applicable
96 Angiogenesis Inhibitors Phase 4,Not Applicable
97 Angiogenesis Modulating Agents Phase 4,Not Applicable
98
leucovorin Approved Phase 3,Not Applicable 58-05-9 143 6006
99
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
100
Acetylcholine Approved, Investigational Phase 2, Phase 3,Not Applicable 51-84-3 187
101
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
102
Dutasteride Approved, Investigational Phase 3,Phase 1 164656-23-9 6918296 152945
103
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
104
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
105
Bexarotene Approved, Investigational Phase 2, Phase 3 153559-49-0 82146
106
Copper Approved, Investigational Phase 3,Phase 1,Phase 2 7440-50-8 27099
107
Benzocaine Approved, Investigational Phase 2, Phase 3,Phase 3 1994-09-7, 94-09-7 2337
108
tannic acid Approved Phase 2, Phase 3,Phase 3 1401-55-4
109
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
110
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Not Applicable 59-30-3 6037
111
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 68-26-8, 22737-96-8, 11103-57-4 9904001 445354
112
Histidine Approved, Nutraceutical Phase 3,Phase 1,Phase 2 71-00-1 6274
113 Garlic Approved, Nutraceutical Phase 3
114 Folic Acid Antagonists Phase 3
115 Nucleic Acid Synthesis Inhibitors Phase 3
116 Vitamin B Complex Phase 3,Not Applicable
117 Vitamin B9 Phase 3,Not Applicable
118 Antimetabolites Phase 3,Phase 1
119 Folate Phase 3,Not Applicable
120 Antimetabolites, Antineoplastic Phase 3
121 Botulinum Toxins Phase 2, Phase 3,Not Applicable
122 Acetylcholine Release Inhibitors Phase 2, Phase 3,Not Applicable
123 abobotulinumtoxinA Phase 2, Phase 3,Not Applicable
124 Botulinum Toxins, Type A Phase 2, Phase 3,Not Applicable
125 Neuromuscular Agents Phase 2, Phase 3,Not Applicable
126 Cholinergic Agents Phase 2, Phase 3,Not Applicable
127 Neurotransmitter Agents Phase 2, Phase 3,Phase 1,Not Applicable,Early Phase 1
128 Micronutrients Phase 3,Phase 1,Phase 2,Not Applicable
129 Nutrients Phase 3,Phase 1,Phase 2,Not Applicable
130 Trace Elements Phase 3,Phase 1,Phase 2,Not Applicable
131 Retinol palmitate Phase 3
132 retinol Phase 3
133 Hydrocortisone hemisuccinate Phase 3
134 Hydrocortisone-17-butyrate Phase 3
135 Hydrocortisone 17-butyrate 21-propionate Phase 3
136 Gentamicins Phase 2, Phase 3
137
Beclomethasone Phase 2, Phase 3 4419-39-0 20469
138
Aldesleukin Approved Phase 1, Phase 2 110942-02-4, 85898-30-2
139
Zinc Approved, Investigational Phase 1, Phase 2,Not Applicable 7440-66-6 32051
140
Nitric Oxide Approved Phase 1, Phase 2 10102-43-9 145068
141
Ethanol Approved Phase 2,Phase 1,Not Applicable 64-17-5 702
142
Phylloquinone Approved, Investigational Phase 2 84-80-0
143 Menaquinone Approved, Investigational Phase 2 1182-68-9
144
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
145
Abatacept Approved Phase 2 332348-12-6 10237
146
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
147
Racepinephrine Approved Phase 2 329-65-7 838
148
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
149
Docetaxel Approved, Investigational Phase 2,Not Applicable 114977-28-5 148124
150
Vitamin C Approved, Nutraceutical Phase 1, Phase 2,Phase 2,Not Applicable 50-81-7 54670067 5785
151
Menadione Approved, Nutraceutical Phase 2 58-27-5 4055
152
Maleic acid Experimental, Investigational Phase 1, Phase 2 110-17-8, 110-16-7 444972
153 Tempol Investigational Phase 2 2226-96-2
154 Histone Deacetylase Inhibitors Phase 2
155
s 1 (combination) Phase 1, Phase 2
156 Interleukin-2 Phase 1, Phase 2
157 Zinc Supplement Phase 1, Phase 2
158 Chelating Agents Phase 1, Phase 2,Not Applicable
159 Free Radical Scavengers Phase 1, Phase 2
160 Bronchodilator Agents Phase 1, Phase 2
161 Antioxidants Phase 1, Phase 2,Phase 2,Not Applicable
162 Endothelium-Dependent Relaxing Factors Phase 1, Phase 2
163 Radiation-Protective Agents Phase 2
164 Anti-Infective Agents, Local Phase 2
165 HIV Protease Inhibitors Phase 2
166
protease inhibitors Phase 2
167 Proteasome Inhibitors Phase 2
168 Ammonium trichloro(dioxoethylene-O,O'-)tellurate Phase 2
169 Antiviral Agents Phase 2
170 Vitamins Phase 2,Phase 1,Not Applicable
171 Androgens Phase 2,Phase 1
172 Androgen Antagonists Phase 2,Phase 1
173 Mitogens Phase 2,Phase 1,Not Applicable
174 Antifibrinolytic Agents Phase 2
175 Vitamin K Phase 2
176 Antineoplastic Agents, Immunological Phase 2
177 Hemostatics Phase 2
178 Coagulants Phase 2
179 Vitamin K 3 Phase 2
180 naphthoquinone Phase 2
181 Calamus Phase 2
182 Antimanic Agents Phase 2,Early Phase 1
183 Psychotropic Drugs Phase 2,Early Phase 1
184 Tranquilizing Agents Phase 2,Early Phase 1
185 Anticonvulsants Phase 2,Early Phase 1
186 GABA Agents Phase 2
187 Epinephryl borate Phase 2
188
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
189 Antimitotic Agents Phase 2,Not Applicable
190 Antibodies Phase 2
191 Immunoglobulins Phase 2
192 Antibodies, Monoclonal Phase 2
193
Bicalutamide Approved Phase 1 90357-06-5 2375 56069
194
Ezetimibe Approved Phase 1 163222-33-1 150311
195
Simvastatin Approved Phase 1 79902-63-9 54454
196
Testosterone undecanoate Approved, Investigational Phase 1 5949-44-0
197
Methyltestosterone Approved Phase 1 58-18-4 6010
198
Testosterone Approved, Experimental, Investigational Phase 1 58-22-0, 481-30-1 10204 6013
199
Testosterone enanthate Approved Phase 1 315-37-7 9416
200
Tacrolimus Approved, Investigational Phase 1 104987-11-3 6473866 445643 439492
201
Norepinephrine Approved Phase 1 51-41-2 439260
202 Estrogens Phase 1
203 Lipid Regulating Agents Phase 1
204 Anticholesteremic Agents Phase 1
205 Ezetimibe, Simvastatin Drug Combination Phase 1
206 Hypolipidemic Agents Phase 1
207 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 1
208 Testosterone 17 beta-cypionate Phase 1
209 Anabolic Agents Phase 1
210 Estrogens, Conjugated (USP) Phase 1
211 Vasoconstrictor Agents Phase 1,Not Applicable
212 Adrenergic alpha-Agonists Phase 1
213 Sympathomimetics Phase 1
214 Adrenergic Agents Phase 1
215 Adrenergic Agonists Phase 1
216
Sodium Citrate Approved, Investigational Not Applicable 68-04-2
217
Ethinyl Estradiol Approved 57-63-6 5991
218
Polyestradiol phosphate Approved 28014-46-2
219
Cyproterone Acetate Approved, Investigational 427-51-0
220
Estradiol Approved, Investigational, Vet_approved 50-28-2 5757